Management of a Positive Fecal Immunochemical Test (FIT)

Primary Management: Colonoscopy

The U.S. Multi-Society Task Force on Colorectal Cancer recommends colonoscopy as the only follow-up test for all screen-eligible individuals with positive FIT results, with strong evidence supporting this approach 1, 2, 3
Colonoscopy directly evaluates the entire colorectal mucosa and simultaneously allows removal of significant neoplasia when detected, making it superior to all other diagnostic modalities 1, 2
The positive predictive value for significant neoplasia is high when FIT returns positive, justifying immediate colonoscopic evaluation regardless of other clinical features like anemia 1, 3

Healthcare systems should aim for ≥95% of follow-up colonoscopies performed within 6 months, with at least 80% offered appointments within 3 months 2, 3, 4

The American Gastroenterological Association recommends not to routinely order upper endoscopy (EGD) based solely on a positive FIT 2
In the absence of iron deficiency anemia or signs/symptoms of upper gastrointestinal pathology, a positive FIT with negative colonoscopy should NOT prompt upper gastrointestinal evaluation 1, 2
Consider EGD only if iron deficiency anemia is present at the time of positive FIT, or if active upper GI symptoms exist (dysphagia, persistent nausea/vomiting, epigastric pain) 2

If a patient has a positive FIT but underwent colonoscopy recently, generally offer repeat colonoscopy, considering clinical context, patient risk factors for advanced neoplasia, and prior colonoscopy quality 1
Patients do NOT need to adjust diet, anticoagulation, or antiplatelet agents when using FIT-based screening 1
Unlike guaiac-based tests, FIT is not confounded by dietary intake of foods with peroxidase activity 1
Aspirin, warfarin, and clopidogrel do not negatively impact FIT test characteristics and may actually improve sensitivity without decreasing specificity 1

Programs should track all positive FIT results and attempt outreach in 100% of patients within ≤2 weeks of test results 4
System-level navigation programs that contact patients by telephone to schedule appointments increase adherence to colonoscopy follow-up 4

During resource-limited situations, colonoscopy following positive FIT can be delayed up to 6 months without negatively impacting patient outcomes 5, 6
Delays of 7-9 months show nonsignificant increased risk, but delays beyond 12 months show profound risk increase 5
Colonoscopy for positive FIT is considered non-time-sensitive and can be delayed beyond 8 weeks during pandemics or resource constraints 5, 6

Never use FIT as a diagnostic test in patients with visible blood in stool—these patients require direct colonoscopy without preliminary FIT testing 7
Never assume a negative colonoscopy after positive FIT requires upper GI evaluation unless iron deficiency anemia or upper GI symptoms are present 1, 2

Refusing colonoscopy after a positive stool‑based DNA test increases colorectal‑cancer‑specific mortality by 1.64‑fold and raises the risk of presenting with advanced‑stage disease (stage III/IV) by up to 3.22‑fold when the delay exceeds 12 months. – U.S. Multi‑Society Task Force on Colorectal Cancer (strong evidence) 8
In patients with a positive FIT, failure to undergo colonoscopy is associated with a 64 % higher risk of death from colorectal cancer compared with those who complete the procedure. – U.S. Multi‑Society Task Force on Colorectal Cancer (strong evidence) 9
Delays of 10–12 months after a positive test increase the odds of advanced‑stage disease by 97 %; delays >12 months raise this odds to 222 % (OR ≈ 3.22 for advanced disease). – U.S. Multi‑Society Task Force on Colorectal Cancer (strong evidence) 10

A higher perceived threat of cancer (patient belief that cancer is likely) independently predicts willingness to undergo colonoscopy (adjusted OR = 1.62). – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 10
Counselors should explicitly state the mortality and advanced‑stage risks associated with refusal, using the quantitative data above, to ensure patients understand the seriousness of non‑adherence. – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 11

When a patient needs time to decide, schedule colonoscopy within 3 months of the positive result; the absolute maximum acceptable interval is 6 months. – U.S. Multi‑Society Task Force on Colorectal Cancer (strong evidence) 10

Immediate appointment scheduling (within 2 weeks of the positive result) significantly improves colonoscopy completion rates. – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 10
Implement patient‑navigation phone outreach within 2 weeks of the positive test; navigation programs have been shown to markedly increase colonoscopy uptake. – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 10
Document every refusal and establish a tracking system so that 100 % of patients with a positive test receive at least one outreach attempt. – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 10
Routinely assess system barriers (e.g., scheduling difficulty, transportation, cost, communication gaps) that may contribute to refusal, and address them proactively. – U.S. Multi‑Society Task Force on Colorectal Cancer (moderate evidence) 10

CT colonography should not be offered as a routine alternative to colonoscopy; it is permissible only when the patient has absolute contraindications to colonoscopy (e.g., severe cardiopulmonary disease precluding sedation). – American College of Radiology (moderate evidence) 12